01—Abstract
Summary
Summary of the 10-Q filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.
GE HealthCare Technologies Inc. reported solid revenue growth in the second quarter of 2026, with total revenues increasing by 5.7% year-over-year to $5.3 billiona, driven by strong performance in its Advanced Imaging Solutions (AIS) and Pharmaceutical Diagnostics (PDx) segments.
The company also benefited from the acquisition of Intelerad, which was integrated into the AIS segment. Net income attributable to GE HealthCare increased by 15.5% to $561 millionb, reflecting improved operational efficiencies and the positive impact of tariff refunds. Despite global macroeconomic uncertainties and supply chain challenges, GE HealthCare demonstrated resilience.
The company successfully navigated the impact of tariffs through strategic pricing and the benefit of tariff refunds, which significantly boosted gross profit. However, the Patient Care Solutions (PCS) segment experienced a decline in revenue due to operational and fulfillment challenges. Looking ahead, the company remains focused on driving innovation and integrating strategic acquisitions while managing inflationary pressures and geopolitical risks.
02—Key points
Key Highlights
- Total revenues for Q2 2026 increased by 5.7% to $5.3 billion, with organic revenue growth of 3.5%.
- Net income attributable to GE HealthCare rose by 15.5% to $561 million, indicating improved profitability.
- The Advanced Imaging Solutions (AIS) segment showed robust growth of 7.9% (5.0% organically), bolstered by the Intelerad acquisition.
- Pharmaceutical Diagnostics (PDx) segment revenue grew significantly by 15.6% (14.6% organically), driven by volume and price increases.
- The Patient Care Solutions (PCS) segment saw a revenue decline of 13.3% due to operational and fulfillment issues.
- The company received $107 million in tariff refunds and recognized $106 million in pre-tax benefits, mitigating the impact of tariffs.
- Cash from operating activities increased by 33.0% to $458 million for the first six months of 2026, with free cash flow up 70.0% to $180 million.
03—Questions
Frequently Asked Questions
What were the main drivers of revenue growth in the second quarter of 2026?
Revenue growth was primarily driven by strong performance in the Advanced Imaging Solutions (AIS) and Pharmaceutical Diagnostics (PDx) segments, increased by the acquisition of Intelerad, and a rise in service revenues due to new and existing customer agreements. Product sales also saw an increase, particularly in PDx and AIS.
How did the company manage the impact of tariffs?
GE HealthCare benefited from tariff refunds, receiving $107 million and recognizing $106 million in pre-tax benefits in Q2 2026. These refunds, along with strategic pricing and volume growth, helped offset the negative impact of tariffs on operating income and gross profit. The company continues to monitor the impact of tariffs and trade restrictions.
What is the outlook for the Patient Care Solutions (PCS) segment?
The PCS segment experienced a revenue decline of 13.3% in Q2 2026 due to operational and fulfillment challenges. The company is actively working to address these issues, but segment performance remains a point of concern.
What are the key acquisitions completed and their impact?
The company completed the acquisition of Intelerad in March 2026 for $2.3 billion, which is now part of the AIS segment and contributed to its revenue growth. The acquisition of icometrix was completed in November 2025, and the acquisition of Nihon Medi-Physics (NMP) was completed in March 2025, impacting the PDx segment.
04—Continue